从PARP1-HPF1复合体中缓慢解离,驱动抑制剂的功效
Petra Stojanovic1, Karolin Luger1,2, Johannes Rudolph1
1Department of Biochemistry, University of Colorado Boulder, Boulder, Colorado 80309, United States.
Biochemistry
|August 2, 2023
概括
聚 (ADP-ribose) 聚合酶抑制剂 (PARPi) 当它们与PARP1-HPF1复合体的解离速率缓慢时,其效能会增加. 这一发现指导了下一代PARPi用于癌症治疗的开发.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多 (ADP-ribose) 聚合酶1 (PARP1) 对于通过多ADP-ribosylation (PARylation) 进行DNA修复至关重要.
- HPF1作为辅助因子,改变PARP1的活性部位,并将PARylation指向组织蛋白.
- PARP1抑制剂 (PARPi) 功效的机制,特别是HPF1,仍然不清楚.
研究的目的:
- 研究各种PARPi与PARP1-HPF1复合体的结合动力学.
- 为了确定与PARPi细胞功率相关的关键动力参数.
- 为了指导下一代PARPi的合理设计.
主要方法:
- 对八个PARPi与PARP1结合的测量关联率 (k_on)
- 特定的PARPi与PARP1-HPF1复合体的特征解离率 (k_off) 和结合常量 (K_D).
- 与细胞内PARPi强度相关的运动参数.
主要成果:
- 与PARP1的PARPi关联率 (k_on) 显示出与HPF1.1或没有HPF1.1的微小差异.
- 沙鲁帕里布的分离半衰期为22.5小时;在HPF1.1的存在下,弗卢佐帕里布对PARP1表现出更高的亲和力.
- PARPi细胞功效与来自PARP1-HPF1复合物的解离率 (k_off) 有着强烈的相关性.
结论:
- 与PARP1-HPF1复合体的解离率是PARPi疗效的关键决定因素.
- 从PARP1-HPF1复合体中缓慢解离药是提高PARPi功效的关键.
- 从PARP1-HPF1复合体中解离动力学应该指导未来的PARPi药物开发.
更多相关视频
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
4.0K
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
9.8K
相关概念视频
Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
199
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
199
Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K
